Why Elan Shares Plunged

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of drug developer Elan (UNKNOWN: ELN.DL2  ) sank 10% today after agreeing to sell its interest in multiple sclerosis drug Tysabri to partner Biogen Idec (NASDAQ: BIIB  ) for $3.25 billion in cash plus future royalties.

So what: The deal ends Elan's 50-50 split arrangement with Biogen for the blockbuster Tysabri, which generated $1.6 billion in sales in 2012, but gives management plenty of fresh cash for future acquisitions. Unfortunately for Elan bulls, the news also squashes recent rumors that Biogen would purchase Elan outright, forcing short-term speculators who were betting on a takeover to race for the exits.

Now what: Elan will still receive a significant royalty for Tysabri, amounting to 12% of annual sales in the first 12 months after the deal closes, then 18% of sales up to $2 billion and 25% of sales over $2 billion.

"The restructuring of this business collaboration provides Elan with significant strategic flexibility," said Elan CEO Kelly Martin. "We are enthusiastic about the market opportunities around the globe and remain flexible and creative about the manner in which we would participate in those opportunities."

With the Elan shares now down about 40% from its 52-week high, today's pullback might even be providing a good opportunity bet on that bullishness.

Interested in more info on Elan? Add it to your watchlist.

How about Biogen Idec? Add it to your watchlist.

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 07, 2013, at 11:42 AM, kickbishopbrenna wrote:

    ELAN goes once more form being a "one trick pony" to a no trick pony..far too risky a stock to be involved in..i got lucky: bought at 1.00 and sold at 6.00 never ventured back...Exelixis has similar risk and profile, but more potential now.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2240172, ~/Articles/ArticleHandler.aspx, 9/27/2016 9:53:49 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,092.36 -2.47 -0.01%
S&P 500 2,148.74 2.64 0.12%
NASD 5,265.01 7.51 0.14%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 9:37 AM
BIIB $309.00 Down -0.82 -0.26%
Biogen CAPS Rating: *****
ELN.DL2 $0.00 Down +0.00 +0.00%
Elan CAPS Rating: ***